Skip to main content

Table 2 Patient characteristics at week 52 by low disease activity at week 208 in the adalimumab discontinuation groupa

From: Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study

  LDA at week 208 (n = 59) Failed LDA at week 208 (n = 15) p Value b
Mean SD Mean SD
Female sex, n (%) 49 83.1 12 80.0 1.0000
Age, years 54.1 11.5 55.8 15.9 0.4675
Disease duration, years 1.3 0.3 1.2 0.3 0.4079
MTX dose, mg/week 7.3 2.0 6.5 1.6 0.2432
Steroid use, n (%) 14 23.7 3 20.0 1.0000
TJC28 0.9 2.0 1.3 1.9 0.2210
SJC28 0.4 0.9 0.4 0.9 0.9329
CRP, mg/dl 0.1 0.2 0.2 0.1 0.0026c
ESR, mm/h 16.4 11.2 25.9 16.7 0.0154d
EGA 7.2 6.9 9.1 8.0 0.4145
PGA 7.2 8.4 13.5 17.5 0.1600
Pain VAS 7.5 7.8 12.6 17.2 0.3242
DAS28-ESR 2.3 0.7 2.8 0.9 0.0113d
DAS28-CRP 1.7 0.6 2.0 0.7 0.0715
HAQ 0.197 0.298 0.208 0.330 0.9240
Erosion 6.5 5.4 9.7 18.9 0.7467
JSN 6.3 9.1 8.3 23.5 0.1199
mTSS 12.8 12.8 18.0 42.2 0.2390
MMP-3, ng/ml 59.0 47.4 67.8 51.9 0.2475
RF 32.3 33.0 83.1 85.3 0.0077c
ACPA, U/ml 113.4 237.9 620.5 1334.9 0.0113d
  1. Abbreviations: ADA Adalimumab, LDA Low disease activity, MTX Methotrexate, TJC Tender joint count, SJC Swollen joint count, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, EGA Evaluator global assessment, PGA Patient global assessment, VAS Visual analogue scale, DAS28 28-joint Disease Activity Score, HAQ Health Assessment Questionnaire, JSN Joint space narrowing, mTSS Modified total Sharp score, MMP-3 Matrix metalloproteinase 3, RF Rheumatoid factor, ACPA Anti-cyclic citrullinated peptide antibody
  2. a Values are expressed as mean ± SD, unless otherwise indicated
  3. b Statistical significance assessed by Fisher’s exact test for categorical data and the Wilcoxon rank sum test for continuous data
  4. c p < 0.01 LDA vs. failed LDA at week 208
  5. d p < 0.05 LDA vs. failed LDA at week 208